PFM Health Sciences’s AstraZeneca AZN Stock Holding History

PFM Health Sciences’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,898	Closed	-$4.74M	–	81
2025 Q3	$4.74M	Buy	+30,898	New	+$4.68M	0.36%	53
2025 Q2	–	Sell	-75,100	Closed	-$11M	–	59
2025 Q1	$11M	Buy	+75,100	New	+$10.9M	0.8%	32
2023 Q1	–	Sell	-288,400	Closed	-$39.1M	–	82
2022 Q4	$39.1M	Hold	288,400	–	–	1.4%	31
2022 Q3	$31.6M	Hold	288,400	–	–	1.14%	41
2022 Q2	$38.1M	Buy	288,400 +62,250	+28%	+$8.17M	1.45%	28
2022 Q1	$30M	Sell	226,150 -166,724	-42%	-$20M	1.12%	39
2021 Q4	$45.8M	Hold	392,874	–	–	1.56%	29
2021 Q3	$47.2M	Buy	392,874 +288,574	+277%	+$33.6M	1.39%	31
2021 Q2	$12.5M	Sell	104,300 -300,900	-74%	-$33M	0.39%	59
2021 Q1	$40.3M	Sell	405,200 -142,100	-26%	-$14.3M	1.23%	28
2020 Q4	$54.7M	Buy	547,300 +353,350	+182%	+$37.4M	1.92%	15
2020 Q3	$21.3M	Sell	193,950 -123,850	-39%	-$13.8M	0.98%	40
2020 Q2	$33.6M	Buy	+317,800	New	+$32.8M	1.74%	19

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PFM Health Sciences's AZN Position: Q4 2025 in Review

PFM Health Sciences sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 30,898 shares — an estimated $4.74M sold.

PFM Health Sciences first reported a position in AZN in Q2 2020 and held it in 13 quarters. The position peaked at $54.7M in Q4 2020. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

PFM Health Sciences reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
PFM Health Sciences sold 30,898 AstraZeneca shares in Q4 2025, an estimated $4.74M.
PFM Health Sciences first reported a position in AstraZeneca in Q2 2020 and held it in 13 quarters.
PFM Health Sciences's AstraZeneca position peaked at $54.7M in Q4 2020.
1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on PFM Health Sciences's 13F filing for Q4 2025, filed 17 Feb 2026.